All In Biotech

Drug Trial Radar · NCT03412799

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: May 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jun 4, 2018

Primary completion

Feb 28, 2022

Study completion Feb 28, 2022

Sponsor

Lead sponsor
Panbela Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.

Conditions

  • Pancreatic Cancer Metastatic
  • Pancreatic Cancer Stage IV
  • Stage IV Pancreatic Cancer

Interventions

  • SBP-101Drug

    Administered as subcutaneous (SC) injection, escalating dose cohorts

  • nab-paclitaxelDrug

    Administered as intravenous (IV) infusion

  • Gemcitabine InjectionDrug

    Administered as intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended dose of SBP-101Time frame: Up to 12 months following the first dose of treatment

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Scripps MD Anderson Cancer Center

    La Jolla, California

  • University of Florida

    Gainesville, Florida

  • University of Rochester Medical Center

    Rochester, New York

  • Blacktown Cancer & Haematology Centre

    Blacktown, New South Wales, Australia

  • John Flynn Private Hospital

    Tugun, Queensland, Australia

  • Ashford Cancer Centre

    Kurralta Park, South Australia, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.